Following men with testicular cancer to track relapse and long-term effects of treatment
Follows adults newly diagnosed with testicular cancer to record relapse and late treatment effects.
Key facts
- Who runs it
- Dr. med. Christian Rothermundt
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
- Status
- Recruiting
- People taking part
- 6,900 people, planned
- Started
- Dec 2013
- Expected to end
- Dec 2033
- Type of study
- Observational
- Record updated
- 13 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with newly diagnosed testicular cancer (seminoma or non-seminoma) who finished treatment in the last 6 months. It follows them over time to check for relapse and long-term side effects.
- Age
- 18 Years and older
- Sex
- Men only
- Disease stage
- Seminoma: complete remission (CR), or lymph nodes < 3cm (1.2 in), or partial remission (PR) with a negative PET scan. Non-seminoma: complete remission (CR).
- Earlier treatment
- Treatment must have been completed within the last 6 months.
- Biomarker or test result
- The cancer must be confirmed by tissue examination (histologically proven).
Main reasons for not taking part
- Another cancer within 5 years
- Unable for any reason to follow the trial tests or follow-up schedule
- Unable or unwilling to come for regular check-ups
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Written informed consent
- Histologically proven seminomas or non-seminoma
- Seminoma: complete remission (CR) or lymph nodes (LN) < 3cm or PET negative partial remission (PR) or non-seminoma: CR
- Completion of treatment within the last 6 months
- Patient able and willing to attend for regular surveillance
Who cannot take part
- Co-existent malignancy within 5 years
- Inability for any reason to comply with the trial investigations or follow-up schedules
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The majority of testicular cancer patients can be cured with cisplatin-based chemotherapy. Mortality has been reduced even more within the last 15 years due to the stringent application of standard chemotherapy followed by resection of residual disease. This is a positive development considering that testicular cancer usually affects young men. Active surveillance has become an acceptable and widely used strategy in stage I testicular cancer. Thus, it is important to follow these patients in a standardized way and to adhere to a rationale surveillance strategy. There is no international consensus regarding follow-up of testicular cancer patients. Stratification according to risks and patterns of relapse would allow to tailor follow-up schedules, aiming at early identification of relapse without causing unnecessary harm by using excessive radiation in these young long-term survivors. Follow-up procedures should not only aim at detecting relapse, but also long-term side effects from therapy, including hypogonadism, metabolic syndrome, cardiovascular disease and secondary malignancies. The Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) will comprise consecutive newly diagnosed testicular cancer patients and is the first study to prospectively evaluate the initial indictor of relapse in testicular cancer patients, the frequency and pattern of relapse and document long-term toxicities of the treatment (cardiovascular, gonadal, hearing impairment, renal function and second malignancies) and psychosocial aspects. This cohort study will determine the relevance of each test performed routinely during follow-up. The collected data will have direct implications for the care of patients with testicular cancer and inform future adaptations of follow-up recommendations. The dataset will give information on baseline factors of testicular cancer patients patients, current treatment strategies in Switzerland, Austria and Germany, outcome and late sequelae.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
- Plain-language title
- Following men with testicular cancer to track relapse and long-term effects of treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Publications
- Record updated
- 13 January 2026